JP2006522750A5 - - Google Patents

Download PDF

Info

Publication number
JP2006522750A5
JP2006522750A5 JP2006504357A JP2006504357A JP2006522750A5 JP 2006522750 A5 JP2006522750 A5 JP 2006522750A5 JP 2006504357 A JP2006504357 A JP 2006504357A JP 2006504357 A JP2006504357 A JP 2006504357A JP 2006522750 A5 JP2006522750 A5 JP 2006522750A5
Authority
JP
Japan
Prior art keywords
phenyl
alkyl
aryl
methyl
methanone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006504357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006522750A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2004/000254 external-priority patent/WO2004089416A2/fr
Publication of JP2006522750A publication Critical patent/JP2006522750A/ja
Publication of JP2006522750A5 publication Critical patent/JP2006522750A5/ja
Pending legal-status Critical Current

Links

JP2006504357A 2003-04-11 2004-04-06 代謝性症候群ならびに関連の疾患および障害を治療するために、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤および抗高血圧剤を使用する併用療法 Pending JP2006522750A (ja)

Applications Claiming Priority (30)

Application Number Priority Date Filing Date Title
DKPA200300571 2003-04-11
DKPA200300567 2003-04-11
DKPA200300569 2003-04-11
DKPA200300570 2003-04-11
DKPA200300566 2003-04-11
DKPA200300565 2003-04-11
US46728403P 2003-05-02 2003-05-02
US46736303P 2003-05-02 2003-05-02
US46745303P 2003-05-02 2003-05-02
US46780003P 2003-05-02 2003-05-02
US46743703P 2003-05-02 2003-05-02
US46736203P 2003-05-02 2003-05-02
DKPA200300776 2003-05-22
DKPA200300777 2003-05-22
US47442103P 2003-05-30 2003-05-30
US47515703P 2003-06-02 2003-06-02
DKPA200300972 2003-06-27
DKPA200300988 2003-06-30
DKPA200300990 2003-06-30
DKPA200300989 2003-06-30
DKPA200300998 2003-07-02
US48609803P 2003-07-10 2003-07-10
US48609503P 2003-07-10 2003-07-10
US48609403P 2003-07-10 2003-07-10
US48607803P 2003-07-10 2003-07-10
US48609703P 2003-07-10 2003-07-10
DKPA200301910 2003-12-22
DKPA200400009 2004-01-06
US53709904P 2004-01-16 2004-01-16
PCT/DK2004/000254 WO2004089416A2 (fr) 2003-04-11 2004-04-06 Polytherapie utilisant un inhibiteur de type 1 de la 11beta-hydroxysteroide deshydrogenase et un agent hypotenseur dans le traitement du syndrome metabolique et des troubles et maladies associes

Publications (2)

Publication Number Publication Date
JP2006522750A JP2006522750A (ja) 2006-10-05
JP2006522750A5 true JP2006522750A5 (fr) 2007-05-24

Family

ID=56290539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006504357A Pending JP2006522750A (ja) 2003-04-11 2004-04-06 代謝性症候群ならびに関連の疾患および障害を治療するために、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤および抗高血圧剤を使用する併用療法

Country Status (2)

Country Link
JP (1) JP2006522750A (fr)
WO (1) WO2004089416A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7532385B2 (ja) 2019-01-31 2024-08-13 杏林製薬株式会社 15-pgdh阻害薬

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482747T1 (de) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
ATE464283T1 (de) 2003-11-21 2010-04-15 Givaudan Sa N-substituierte p-menthancarbonsäureamide
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2005108360A1 (fr) 2004-05-07 2005-11-17 Janssen Pharmaceutica N.V. Utilisation de derives de pyrrolidin-2-one et de piperidin-2-one comme inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase
GB0418877D0 (en) * 2004-08-24 2004-09-29 Univ Edinburgh Heart
EA012263B1 (ru) 2004-08-30 2009-08-28 Янссен Фармацевтика Н.В. Производные n-2-адамантанил-2-феноксиацетамида в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
CN101039908B (zh) 2004-08-30 2010-06-23 詹森药业有限公司 作为11-β羟甾类脱氢酶抑制剂的三环内酰胺衍生物
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
BRPI0515483A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
EP1804799B1 (fr) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'agents thérapeutiques
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリダジン誘導体
JP5043668B2 (ja) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
JP2008518003A (ja) * 2004-10-29 2008-05-29 アストラゼネカ・アクチエボラーグ 医薬品としての不飽和キノリンもしくはナフタレン誘導体の使用
EP1812407A2 (fr) * 2004-11-02 2007-08-01 Pfizer, Inc. Nouveaux composes d'adamantyl amides substitues ou non
MX2007005940A (es) 2004-11-18 2007-06-19 Synta Pharmaceuticals Corp Compuestos de triazol que modulan la actividad hsp90.
WO2006074330A2 (fr) 2005-01-05 2006-07-13 Abbott Laboratories Inhibiteurs de l'enzyme 11-beta-hydroxysteroide dehydrogenase de type 1
ES2386365T3 (es) 2005-01-05 2012-08-17 Abbott Laboratories Derivados de adamantilo como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa de tipo 1
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
FR2880887B1 (fr) * 2005-01-14 2009-01-30 Merck Sante Soc Par Actions Si Derives d'hydroxyphenols, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
AU2006222372B8 (en) * 2005-03-03 2010-04-08 F. Hoffmann-La Roche Ag 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type II diabetes mellitus
US20080153791A1 (en) * 2005-03-18 2008-06-26 Onpharm Gmbh 11Beta -Hydroxysteroid Dehydrogenases
GB0506133D0 (en) * 2005-03-24 2005-05-04 Sterix Ltd Compound
ES2369389T3 (es) 2005-04-05 2011-11-30 F. Hoffmann-La Roche Ag 1h-pirazol-4-carboxamidas, su preparación y su empleo como inhibidores de 11-beta- hidroxiesteroide dehidrogenasa.
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
WO2007094819A2 (fr) 2005-08-18 2007-08-23 Synta Pharmaceuticals Corp. Dérivés de triazole modulant l'activité de hsp90
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
GB2429975A (en) * 2005-09-08 2007-03-14 Univ Edinburgh 1,5-substituted-1H-tetrazole 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
KR20080063806A (ko) 2005-10-06 2008-07-07 쉐링 코포레이션 단백질 키나제 억제제로서의 피라졸로피리미딘
WO2007082808A2 (fr) 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
PE20071232A1 (es) * 2006-02-07 2008-02-18 Wyeth Corp Derivados de piperidina o piperazina como inhibidores de 11-beta hsd1
CN101405270B (zh) 2006-03-22 2013-01-16 霍夫曼-拉罗奇有限公司 作为11-β-HSD-1的吡唑类
MX2008012064A (es) 2006-03-23 2008-12-17 Amgen Inc Compuestos de amida 1-fenilsulfonil-diaza-heterociclica y sus usos como moduladores de hidroxiesteroide deshidrogenadas.
TWI490212B (zh) 2006-05-25 2015-07-01 Synta Pharmaceuticals Corp 調節hsp90活性之三唑化合物
PL2054416T3 (pl) 2006-08-04 2011-05-31 Merz Pharma Gmbh & Co Kgaa Podstawione pirazolopirymidyny, sposób ich wytwarzania oraz ich zastosowanie w medycynie
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CA2662574A1 (fr) 2006-09-22 2008-03-27 Novartis Ag Composes organiques
JP5166423B2 (ja) * 2006-10-17 2013-03-21 レヴァ メディカル、 インコーポレイテッド N−置換モノマーおよびポリマー
KR20080052024A (ko) * 2006-12-07 2008-06-11 (주)아모레퍼시픽 아세틸-조효소 a 카복실라제 저해활성을 갖는트리아졸로피리다진 유도체
EA200900820A1 (ru) 2006-12-20 2010-02-26 Новартис Аг 2-замещенные 5-членные гетероциклы в качестве ингибиторов стеароил-соа-десатуразы (ссд)
EP1935420A1 (fr) * 2006-12-21 2008-06-25 Merck Sante Dérivés du 2-adamantyl-butyramide en tant qu'inhibiteurs selectifs de la 11beta-HSD1
JPWO2008078725A1 (ja) * 2006-12-26 2010-04-30 第一三共株式会社 チアゼピン誘導体
WO2008101886A1 (fr) 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides utilisés en tant qu'inhibiteurs de la 11-bêta-hydroxystéroïde déshydrogénase
ZA200904916B (en) 2007-02-23 2010-09-29 High Point Pharmaceuticals Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
EP2146952A1 (fr) 2007-02-23 2010-01-27 High Point Pharmaceuticals, LLC N-adamantylbenzamides utiles comme inhibiteurs de 11-beta-hydroxysteroide deshydrogenase
US20090215778A1 (en) * 2007-04-27 2009-08-27 Panacos Pharmaceuticals, Inc. Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives
BRPI0812775B8 (pt) * 2007-06-07 2021-05-25 Alfasigma Spa uso de 17 beta-(3-furil)-5 beta-androstano-3 beta, 14 beta, 17 alfa- triol na preparação de um medicamento para prevenção ou tratamento de doenças devidas à fibrose hepática
CN101743226B (zh) 2007-07-17 2012-10-10 霍夫曼-拉罗奇有限公司 11β-羟基类固醇脱氢酶抑制剂
CA2695742C (fr) 2007-08-10 2012-11-27 Rudolf Mueller Amides bicycles permettant d'ameliorer les reponses synaptiques glutamateriques
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
AU2009207634B2 (en) * 2008-01-25 2012-12-20 Specialty Operations France Use of ester amides as solvents, ester amides as such, and method for preparing ester amides
EP2349279A4 (fr) * 2008-10-28 2013-12-25 Univ Leland Stanford Junior Modulateurs d'aldéhyde déshydrogénase et procédés d'utilisation de ceux-ci
US8809344B2 (en) 2008-10-29 2014-08-19 Apath, Llc Compounds, compositions, and methods for control of hepatitis C viral infections
CN102223797A (zh) 2008-11-21 2011-10-19 高点制药有限责任公司 金刚烷基苯甲酰胺化合物
EP2243494A1 (fr) * 2009-04-22 2010-10-27 OntoChem GmbH Composition pharmaceutique, renfermant un inhibiteur de la steroid-déshydrogénase-reductase et un antagoniste de récepteurs de minéralocorticoide.
WO2011051342A1 (fr) 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Dérivés d'imidazo[1,2-b]pyridazine et leur utilisation comme inhibiteurs de pde10
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
WO2011133520A1 (fr) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Thérapie anticancéreuse à l'aide d'une combinaison d'un composé inhibiteur de hsp90 et d'un inhibiteur d'egfr
WO2012015715A1 (fr) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Dérivés de thiazol-2-ylamine substitués, compositions pharmaceutiques et procédés d'utilisation en tant que modulateurs de 11-bêta-hsd1
WO2012061039A2 (fr) 2010-10-25 2012-05-10 Vanderbilt University Compositions pour inhiber la capacité d'insectes à détecter des hôtes
GB201103103D0 (en) 2011-02-23 2011-04-06 Givaudan Sa Organic compounds
CA2835328C (fr) * 2011-05-06 2019-10-15 Vanderbilt University Composition destinee a inhiber les perceptions des insectes
EP2723744B1 (fr) 2011-06-27 2016-03-23 Janssen Pharmaceutica, N.V. Dérivés de 1-aryl-4-méthyl-[1,2,4]triazolo[4,3-a]-quinoxaline
CA2853799A1 (fr) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Therapie anticancereuse utilisant une combinaison d'inhibiteurs de hsp 90 et d'inhibiteurs de topoisomerase i
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (fr) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Association thérapeutique d'inhibiteurs de hsp90 et d'inhibiteurs de braf
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
ITMI20120786A1 (it) * 2012-05-09 2013-11-10 Fond Italiana Sclerosi M Ultipla Fism Onlu Modulatori del recettore gpr17
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
WO2014009305A1 (fr) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibiteurs de l'enzyme phosphodiestérase 10
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
US9682028B2 (en) 2013-03-13 2017-06-20 Conopco, Inc. Personal care photoprotective compositions with tricyclodecane amides
EP2969026B1 (fr) 2013-03-13 2017-11-01 Unilever PLC Composition cosmétique contenant les amides de tricyclododecane
MX355874B (es) 2013-03-13 2018-05-02 Unilever Nv Suministro prolongado de ciertos componentes de fragancia de composiciones de cuidado personal.
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
DK2968304T3 (en) 2013-03-14 2019-01-28 Univ Columbia 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE.
EP2968303B1 (fr) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, leur préparation et leur utilisation
EP2970124B1 (fr) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Modulateurs de l'aldéhyde déshydrogénase-2 mitochondriale et leurs procédés d'utilisation
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
CN105228616B (zh) * 2013-03-15 2019-05-03 实发生物医学公司 抗前蛋白转化酶枯草杆菌蛋白酶Kexin 9型(抗PCSK9)化合物及其用于治疗和/或预防心血管疾病的方法
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
CN103420931B (zh) * 2013-05-02 2015-07-08 范国煌 调节巨噬细胞极化并抗糖尿病的五环化合物及其应用
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
CN105829284B (zh) 2013-12-09 2019-01-22 荷兰联合利华有限公司 制备金刚烷甲酰胺类化合物的方法
EP3105219B9 (fr) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
ES2901711T3 (es) 2014-02-13 2022-03-23 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
ME03580B (fr) 2014-02-13 2020-07-20 Incyte Corp Cyclopropylamines en tant qu'inhibiteurs de lsd1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10144742B2 (en) 2014-04-18 2018-12-04 Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof
ES2909793T3 (es) 2014-04-30 2022-05-10 Univ Columbia 4-fenilpiperidinas sustituidas, su preparación y uso
CN106459039A (zh) 2014-05-23 2017-02-22 豪夫迈·罗氏有限公司 为jak抑制剂的5‑氯‑2‑二氟甲氧基苯基吡唑并嘧啶化合物
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
WO2016007727A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
CN107438598A (zh) 2015-01-20 2017-12-05 米伦纽姆医药公司 喹唑啉和喹啉化合物及其用途
US10791739B2 (en) 2015-03-25 2020-10-06 Vanderbilt University Binary compositions as disruptors of orco-mediated odorant sensing
SG11201708047UA (en) 2015-04-03 2017-10-30 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
CA3010615C (fr) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Modulateurs de mastocytes et leurs utilisations
EP3210469A1 (fr) * 2016-02-23 2017-08-30 Bayer Cropscience AG Utilisation des thio-1,2,4-triazoles substitués pour augmenter le tolerance de stress dans des plants
AR109452A1 (es) 2016-04-22 2018-12-12 Incyte Corp Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
JP2020502070A (ja) 2016-11-30 2020-01-23 ケース ウエスタン リザーブ ユニバーシティ 15−pgdh阻害剤とコルチコステロイドおよび/またはtnf阻害剤との組み合わせならびにその使用
JP2020514323A (ja) * 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
CN110891568A (zh) 2017-04-07 2020-03-17 凯斯西储大学 用于治疗冠状动脉病症的短链脱氢酶活性的抑制剂
BR112019024322A2 (pt) 2017-05-22 2020-06-16 F. Hoffmann-La Roche Ag Compostos e composições terapêuticos e métodos de uso dos mesmos
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation
BR112021011578A2 (pt) 2018-12-31 2021-08-31 Biomea Fusion, Llc Inibidores irreversíveis de interação menina-mll
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
CN109966298A (zh) * 2019-05-10 2019-07-05 辽宁大学 托伐普坦在制备降血脂药物中的应用
JP2024534014A (ja) 2021-08-20 2024-09-18 バイオメア フュージョン,インコーポレイテッド 癌の処置のための不可逆的メニン-MLL阻害剤、N-[4-[4-(4-モルホリニル)-7H-ピロロ[2,3-d]ピリミジン-6-イル]フェニル]-4-[[3(R)-[(1-オキソ-2-プロペン-1-イル)アミノ]-1-ピペリジニル]メチル]-2-ピリジンカルボキサミドの結晶形態

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9517622D0 (en) * 1995-08-29 1995-11-01 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
JP2004502432A (ja) * 2000-07-05 2004-01-29 バイエル アクチェンゲゼルシャフト ヒト11β−ヒドロキシステロイドデヒドロゲナーゼ1様酵素の調節
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
AU2003217046A1 (en) * 2002-04-05 2003-10-27 The University Of Edinburgh Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent
WO2004089471A2 (fr) * 2003-04-11 2004-10-21 Novo Nordisk A/S Utilisation pharmaceutique de pyrazolo[1,5-a]pyrimidines substituees

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7532385B2 (ja) 2019-01-31 2024-08-13 杏林製薬株式会社 15-pgdh阻害薬

Similar Documents

Publication Publication Date Title
JP2006522750A5 (fr)
JP2006522744A5 (fr)
US7501405B2 (en) Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
US20060094699A1 (en) Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
JP2006522744A (ja) グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
JP2006522746A5 (fr)
JP2006522750A (ja) 代謝性症候群ならびに関連の疾患および障害を治療するために、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤および抗高血圧剤を使用する併用療法
US20060111366A1 (en) Pharmaceutical use of substituted amides
WO2004089470A2 (fr) Utilisation pharmaceutique d'amides substitues
ES2314750T3 (es) Derivados de 3-fenil-pirazol como moduladores del receptor 5ht-2a de la serotonina utiles para el tratamiento de trastornos relacionados con el mismo.
KR20160005341A (ko) Ampk 활성인자 및 세로토닌성 제제를 포함하는 약학 조성물 및 이의 사용 방법
WO2004089367A1 (fr) Utilisation pharmaceutique de 1,2,4-triazoles substituees
HRP20140030T1 (hr) Derivati prolina kao inhibitori katepsina
US9186353B2 (en) Treatment of osteoarthritis pain
JP2015513552A5 (fr)
IL277579B (en) Piperidinone derivatives as mdm2 inhibitors for cancer therapy
RU2011111592A (ru) Замещенные аминоинданы и их аналоги и их применение в фармацевтике
RU2010130095A (ru) Активаторы глюкокиназы и фармацевтические композиции, содержащие их в качестве активного ингредиента
JP2007502808A5 (fr)
AU2015308522A1 (en) Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases
CA2650566A1 (fr) Compositions pharmaceutiques contenant des modulateurs de recepteurs aux cannabinoides cbx et des modulateurs de canaux potassium
EP1854487A2 (fr) Combinaisons d'un inhibiteur de 11-beta-hydroxystéroïde déhydrogénase, type 1, et d'un agoniste d'un récepteur glucocorticoïde
WO2001095902A1 (fr) Composition contenant une association d'agonistes et d'antagonistes d'un recepteur
EP1862181A2 (fr) Polythérapie utilisant un inhibiteur de la 11B-hydroxystéroïde déshydrogénase de type 1 et agent anti-hypertensif pour le traitement du syndrome métabolique et maladies et troubles associés
WO2001095902A9 (fr) Composition contenant une association d'agonistes et d'antagonistes d'un recepteur